Cardiovascular Biotech Setback: Major Clinical Trial Failures Shake Early-Stage Investment

2026-11-08 biotech

Amsterdam, Sunday 8 November 2026
Despite cutting targeted fatty proteins by 78%, Novartis’s experimental therapy failed to prevent heart attacks in late-stage trials, triggering an urgent valuation review across early-stage European biotechnology developers.

Unprecedented Biomarker Disconnect at AHA 2026

The global cardiovascular biotechnology landscape received a profound shock in Chicago during the American Heart Association (AHA) Scientific Sessions 2026, held from 6 to 9 November 2026 at McCormick Place [4]. Complete findings from the phase III Lp(a)HORIZON study—evaluating Novartis’s antisense oligonucleotide pelacarsen across 8,322 patients in 42 countries over a median duration of 4.7 years—were unveiled on Saturday, 7 November 2026, alongside publication in The New England Journal of Medicine [3][4][6]. Subcutaneous administration of 80 mg pelacarsen achieved a mean reduction in lipoprotein(a) [Lp(a)] levels of 78% [4][6], dropping median concentrations from 236 nmol/L to 64.4 nmol/L at 12 months [5][6]. Yet, this biomarker success translated into an unequivocally neutral clinical outcome: primary major adverse cardiovascular events (MACE) occurred in 12.3% of pelacarsen-treated patients compared with 12.1% in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.90 to 1.15; P=0.76) [4][6]. In participants entering with baseline Lp(a) levels of at least 90 mg/dL, events occurred at an identical 12.309% rate (402 of 3,266 patients) on pelacarsen versus 12.309% (403 of 3,274 patients) on placebo (hazard ratio, 1.00; 95% CI, 0.87 to 1.15; P=0.99) [6].

Dual Failures Dismantle Classic Mechanistic Hypotheses

Compounding the crisis for targeted cardiology, Novo Nordisk presented detailed outcomes from its phase III ZEUS trial during the same late-breaking session on 7 November 2026 [3][4]. Evaluating monthly 15 mg injections of the anti-IL-6 monoclonal antibody ziltivekimab across 6,376 patients with atherosclerotic disease, chronic kidney disease, and elevated inflammatory markers, the therapy lowered interleukin-6 by 76% and high-sensitivity C-reactive protein (hsCRP) by 64% [3][4]. Nevertheless, ziltivekimab delivered a neutral 3-point MACE incidence of 17.6% versus 17.7% for placebo, generating a hazard ratio of 0.99 (95% CI, 0.88 to 1.11) [3][4]. The failure triggered the termination of Novo Nordisk’s companion heart failure programmes, HERMES and ATHENA, after independent data monitors concluded alternative outcomes were improbable [3][4]. Senior trial investigator Dr Steven E. Nissen noted that pelacarsen produced no discernible outcome benefit across any demographic subgroup, leaving clinicians and researchers to reassess whether intermediate circulating biomarkers reliably reflect vascular event prevention [4][6].

Reverberations Across European Life Science Corridors

The simultaneous clinical neutralisation of pelacarsen and ziltivekimab has sent immediate tremors through early-stage biotechnology clusters across the Benelux region, where venture-backed spin-offs from institutions such as KU Leuven, Ghent University, and Leiden University have heavily committed capital to targeted genetic interventions and lipid-modifying platforms [GPT]. Venture capitalists and institutional life sciences funds are now stress-testing lab-to-market pipelines that had predicated exit valuations on the commercial validation of surrogate biomarker suppression [GPT]. Tolerability issues identified in the Lp(a)HORIZON study have introduced additional developmental hurdles: pelacarsen was discontinued by 21% of active participants due to adverse reactions—including 19 instances of anaphylaxis alongside widespread injection and flu-like symptoms—compared to more than 7% in the placebo cohort, with total study discontinuations reaching approximately one-third of subjects [4][6].

Competitive Pipeline Realignment and RNA Modalities

The setback places intense competitive scrutiny on next-generation clinical assets operating in the Lp(a) arena, including small interfering RNA (siRNA) candidates such as Amgen’s olpasiran and Eli Lilly’s lepodisiran [5]. These programmes recruited populations using more stringent baseline cut-offs—200 nmol/L and 175 nmol/L respectively, against the 70 mg/dL threshold (approximately 149 nmol/L) applied in the pelacarsen trial [5]. However, the absence of clinical event divergence even in pelacarsen’s high-baseline cohort of ≥90 mg/dL (hazard ratio, 1.00) indicates that subsequent siRNA drug readouts cannot rely solely on greater pharmacodynamic potencies [5][6]. As European MedTech and biopharma hubs assemble in late November 2026 to evaluate pharma licensing strategies, regional drug developers are compelled to pivot towards multi-target pathways—such as dual siRNA constructs simultaneously inhibiting PCSK9 and Lp(a) or novel precision CRISPR-Cas9 genome editing therapies—to de-risk clinical translation before reaching capital-intensive phase III registrational trials [3][4][5].

Sources & Ecosystem Partners

Cardiovascular Therapeutics Clinical Trials